Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3974991 | 0.87 | KDM4E (0.44) | MTNR1AMTNR1BSIRT2KDM4E | |
| SCHEMBL3984320 | 0.87 | PTGDR2 (0.42) | PPARDMTNR1AMTNR1BSIRT2HDAC1 | |
| SCHEMBL3978617 | 0.86 | MTNR1A (0.53) | MTNR1AMTNR1BHDAC1HDAC2 | |
| SCHEMBL3975780 | 0.86 | MTNR1A (0.53) | MTNR1AMTNR1BHDAC1HDAC2 | |
| SCHEMBL3982083 | 0.86 | MTNR1A (0.53) | MTNR1AMTNR1BHDAC1HDAC2 | |
| SCHEMBL3973759 | 0.85 | MTNR1A (0.51) | MTNR1AMTNR1B | |
| SCHEMBL4283387 | 0.84 | MTNR1A (0.44) | MRGPRX4PPARDMTNR1AMTNR1BKDM4E | |
| SCHEMBL4981179 | 0.84 | MTNR1A (0.46) | MTNR1AMTNR1B | |
| SCHEMBL3984539 | 0.84 | MTNR1A (0.49) | PPARAMTNR1AMTNR1BHDAC1HDAC2 | |
| SCHEMBL3980369 | 0.84 | MTNR1A (0.44) | MRGPRX4MTNR1AMTNR1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2056810-A2 | THIOUREA COMPOUNDS | National Health Research Institutes (TW) | 2009-05-13 | — | — | EP | disclosed |
| US-20080113975-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-05-15 | — | — | US | disclosed |
| US-20080096875-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-04-24 | — | — | US | disclosed |
| WO-2008022204-A2 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096875-A1 | THIOUREA COMPOUNDS | TPMT, HAVCR2, ETV6 | MRGPRX4 2232/4885PPARD 2878/4885PPARA 3361/4885 |
| US-20080113975-A1 | THIOUREA COMPOUNDS | TPMT, HAVCR2, EIF2AK2 | MRGPRX4 2155/4885PPARD 3178/4885PPARA 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.